West Windsor, NJ, United States of America

Divyakant S Desai

This inventor holds 14 USPTO granted patents and 5 published patent applications, plus 2 CIPO patents and 6 EPO patents. Top assignees: Bristol-Myers Squibb Compnay, Astrazeneca Ab, Astra Zeneca U.k. Limited. Active years: 1998-2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Divyakant S Desai. Retrieved from https://idiyas.com/inventor/divyakant-s-desai

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 14 (Patent Applications = 5)

% Patents Active = 71.4

CIPO Patents = 2

EPO Patents = 6 (Patent Applications = 6)

Average Co-Inventor Count = 2.8

ph-index = 5

Forward Citations = 96(Granted Patents)

Location History:

Robbinsville, NJ (US) (1999)
West Windsor, NJ (US) (1998 - 2016)
Princeton, NJ (US) (2013 - 2021)

Company Filing History:

8 out of 3,742

Bristol-Myers Squibb Compnay

Astra Zeneca U.k. Limited

patents

4. 1 out of 1,624

E. R. Squibb Sons, Inc.

patents

5. 1 out of 846

Otsuka Pharmaceutical Company, Limited

where one patent can have more than one assignee

Years Active: 1998-2021

Loading Chart...

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10973768 - Extended release pharmaceutical formulations of water-soluble active pharmaceutical ingredients and methods for making the same (2021-04-13),

2. 9616028 - Bilayer tablet formulations (2017-04-11),

3. 9358207 - Flashmelt oral dosage formulation (2016-06-07),

4. 9339472 - Coated tablet formulation and method (2016-05-17),

5. 9050258 - Bilayer tablet formulations (2015-06-09),

6. 8628799 - Coated tablet formulation and method (2014-01-14),

7. 8535715 - Bilayer tablet formulations (2013-09-17),

8. 8518421 - Flashmelt oral dosage formulation (2013-08-27),

9. 7951400 - Coated tablet formulation and method (2011-05-31),

10. 7507768 - Antidiabetic formulation and method (2009-03-24),

11. 7183321 - Antidiabetic formulation and method (2007-02-27),

12. 6627224 - Low dose entecavir formulation and use (2003-09-30),

13. 5994348 - Pharmaceutical compositions containing irbesartan (1999-11-30),

14. 5801220 - Rapidly disintegrating thickening composition (1998-09-01),

Title: The Innovative Contributions of Divyakant S Desai

Introduction

Divyakant S Desai is a prominent inventor based in West Windsor, NJ (US). He has made significant contributions to the field of pharmaceuticals, holding a total of 14 patents. His work primarily focuses on developing advanced drug formulations that enhance the efficacy and delivery of active pharmaceutical ingredients.

Latest Patents

Among his latest patents, Desai has developed extended-release pharmaceutical formulations of water-soluble active pharmaceutical ingredients. This innovative method involves creating formulations that include an aqueous solution of the active ingredient, which is combined with release-modifying polymers and binders in organic solvents. This process allows for the effective precipitation of the active ingredient, leading to the production of co-processed particles that can be dried and used in dosage forms such as tablets. Another notable patent involves bilayer tablet formulations that combine metformin extended release with SGLT2 inhibitor formulations, providing a novel approach to treating diseases associated with SGLT2 activity.

Career Highlights

Desai has worked with several prestigious companies in the pharmaceutical industry, including Bristol-Myers Squibb Company and AstraZeneca AB. His experience in these organizations has contributed to his expertise in drug formulation and development.

Collaborations

Throughout his career, Desai has collaborated with notable colleagues such as Bing V Li and Admassu Abebe. These partnerships have further enriched his research and innovation in the pharmaceutical field.

Conclusion

Divyakant S Desai's contributions to pharmaceutical innovations demonstrate his commitment to improving drug delivery systems. His patents reflect a deep understanding of pharmaceutical science and a dedication to enhancing patient care through effective medication formulations.

Profile summary based on public USPTO records.